|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBMX2 |
Gene summary for RBMX2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBMX2 | Gene ID | 51634 |
| Gene name | RNA binding motif protein X-linked 2 | |
| Gene Alias | CGI-79 | |
| Cytomap | Xq26.1 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q9Y388 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51634 | RBMX2 | LZE2T | Human | Esophagus | ESCC | 1.17e-12 | 4.95e-01 | 0.082 |
| 51634 | RBMX2 | LZE4T | Human | Esophagus | ESCC | 4.55e-08 | 2.58e-01 | 0.0811 |
| 51634 | RBMX2 | LZE7T | Human | Esophagus | ESCC | 4.16e-06 | 6.41e-01 | 0.0667 |
| 51634 | RBMX2 | LZE8T | Human | Esophagus | ESCC | 9.99e-08 | 1.29e-01 | 0.067 |
| 51634 | RBMX2 | LZE20T | Human | Esophagus | ESCC | 5.40e-10 | 1.55e-01 | 0.0662 |
| 51634 | RBMX2 | LZE24T | Human | Esophagus | ESCC | 5.25e-18 | 5.65e-01 | 0.0596 |
| 51634 | RBMX2 | LZE21T | Human | Esophagus | ESCC | 1.11e-06 | 2.08e-01 | 0.0655 |
| 51634 | RBMX2 | LZE6T | Human | Esophagus | ESCC | 1.08e-02 | 2.53e-01 | 0.0845 |
| 51634 | RBMX2 | P1T-E | Human | Esophagus | ESCC | 1.24e-06 | 4.28e-01 | 0.0875 |
| 51634 | RBMX2 | P2T-E | Human | Esophagus | ESCC | 1.27e-18 | 4.79e-01 | 0.1177 |
| 51634 | RBMX2 | P4T-E | Human | Esophagus | ESCC | 5.91e-28 | 6.97e-01 | 0.1323 |
| 51634 | RBMX2 | P5T-E | Human | Esophagus | ESCC | 1.56e-19 | 3.45e-01 | 0.1327 |
| 51634 | RBMX2 | P8T-E | Human | Esophagus | ESCC | 1.69e-26 | 3.57e-01 | 0.0889 |
| 51634 | RBMX2 | P9T-E | Human | Esophagus | ESCC | 3.83e-20 | 4.79e-01 | 0.1131 |
| 51634 | RBMX2 | P10T-E | Human | Esophagus | ESCC | 4.08e-24 | 6.17e-01 | 0.116 |
| 51634 | RBMX2 | P11T-E | Human | Esophagus | ESCC | 7.49e-15 | 5.06e-01 | 0.1426 |
| 51634 | RBMX2 | P12T-E | Human | Esophagus | ESCC | 1.32e-21 | 2.24e-01 | 0.1122 |
| 51634 | RBMX2 | P15T-E | Human | Esophagus | ESCC | 2.10e-19 | 3.33e-01 | 0.1149 |
| 51634 | RBMX2 | P16T-E | Human | Esophagus | ESCC | 4.39e-24 | 1.58e-01 | 0.1153 |
| 51634 | RBMX2 | P17T-E | Human | Esophagus | ESCC | 1.97e-11 | 2.58e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
| GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
| GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
| GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
| GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBMX2 | SNV | Missense_Mutation | novel | c.91G>A | p.Glu31Lys | p.E31K | Q9Y388 | protein_coding | tolerated(0.15) | benign(0.026) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBMX2 | SNV | Missense_Mutation | novel | c.376N>A | p.Asp126Asn | p.D126N | Q9Y388 | protein_coding | tolerated(0.1) | benign(0.058) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RBMX2 | SNV | Missense_Mutation | rs762680339 | c.647N>T | p.Ser216Leu | p.S216L | Q9Y388 | protein_coding | deleterious(0.01) | benign(0.212) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBMX2 | SNV | Missense_Mutation | novel | c.498N>T | p.Lys166Asn | p.K166N | Q9Y388 | protein_coding | deleterious(0.02) | benign(0.203) | TCGA-VS-A8QH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |
| RBMX2 | SNV | Missense_Mutation | c.631G>A | p.Glu211Lys | p.E211K | Q9Y388 | protein_coding | deleterious(0.02) | benign(0.411) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RBMX2 | SNV | Missense_Mutation | novel | c.41N>G | p.Asn14Ser | p.N14S | Q9Y388 | protein_coding | tolerated(0.13) | benign(0.223) | TCGA-AA-A024-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| RBMX2 | SNV | Missense_Mutation | novel | c.899N>T | p.His300Leu | p.H300L | Q9Y388 | protein_coding | deleterious(0.01) | benign(0.06) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RBMX2 | SNV | Missense_Mutation | c.712C>A | p.Leu238Ile | p.L238I | Q9Y388 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| RBMX2 | SNV | Missense_Mutation | novel | c.503A>C | p.Lys168Thr | p.K168T | Q9Y388 | protein_coding | deleterious(0.05) | benign(0.06) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RBMX2 | SNV | Missense_Mutation | c.713N>C | p.Leu238Pro | p.L238P | Q9Y388 | protein_coding | tolerated(0.33) | benign(0) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |